Upadacitinib
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Axial Spondylarthritis (r-axSpA)
Conditions
Axial Spondylarthritis (r-axSpA)
Trial Timeline
Nov 22, 2021 → Jun 1, 2026
NCT ID
NCT05094128About Upadacitinib
Upadacitinib is a pre-clinical stage product being developed by AbbVie for Axial Spondylarthritis (r-axSpA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05094128. Target conditions include Axial Spondylarthritis (r-axSpA).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04159597 | Pre-clinical | Active |
| NCT06332534 | Phase 3 | Recruiting |
| NCT06773403 | Approved | Recruiting |
| NCT05782907 | Phase 3 | Active |
| NCT05507580 | Approved | Completed |
| NCT05094128 | Pre-clinical | Recruiting |
| NCT04195698 | Phase 3 | Completed |
| NCT03725007 | Phase 1 | Active |
Competing Products
20 competing products in Axial Spondylarthritis (r-axSpA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| Brodalumab + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Adalimumab | AbbVie | Approved | 85 |
| Adalimumab + Placebo + Open-label Adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Treatment | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Phase 3 | 77 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Secukinumab 150 milligram [Cosentyx] | Novartis | Approved | 85 |
| secukinumab | Novartis | Pre-clinical | 23 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 85 |
| Secukinumab + Secukinumab and Placebo | Novartis | Phase 3 | 77 |
| Secukinumab/Adalimumab-Biosimilar | Novartis | Phase 3 | 77 |
| Brodalumab 210 mg + Placebo | Amgen | Phase 2 | 51 |
| Etanercept 25mg + Sulfasalazine | Pfizer | Phase 2 | 51 |